Peptide aggregation poses a significant challenge in biopharmaceutical development and neurodegenerative diseases. This study combines computational simulations and experimental validation to uncover the underlying mechanisms and countermeasures for the aggregation of glucagon, a peptide with a high tendency to aggregate. In silico simulations demonstrate that lactose and 2-hydroxypropyl-beta-cyclodextrin (2-HP beta CD) influence glucagon aggregation differently: lactose stabilizes glucagon by increasing the alpha-helical content, while 2-HP beta CD disrupts protein-protein interactions. According to the simulations, 2-HP beta CD is particularly effective at preserving the monomeric form of glucagon. Experimental validation with microfluidic modulation spectroscopy (MMS) confirms these findings, showing that glucagon in the presence of 2-HP beta CD remains structurally stable, supporting the antiaggregation effect of this excipient. This research provides essential insights into glucagon aggregation obtained through a new powerful tool for monitoring the critical properties of peptide aggregation, suggesting new strategies for addressing this challenge in therapeutic peptide development.

Understanding glucagon aggregation: in silico insights and experimental validation / Pisano, Roberto; Arsiccio, Andrea; Collins, Valerie; King, Patrick; Macis, Marco; Cabri, Walter; Ricci, Antonio. - In: MOLECULAR PHARMACEUTICS. - ISSN 1543-8384. - 21:8(2024), pp. 3815-3823. [10.1021/acs.molpharmaceut.4c00038]

Understanding glucagon aggregation: in silico insights and experimental validation

Pisano, Roberto;Arsiccio, Andrea;
2024

Abstract

Peptide aggregation poses a significant challenge in biopharmaceutical development and neurodegenerative diseases. This study combines computational simulations and experimental validation to uncover the underlying mechanisms and countermeasures for the aggregation of glucagon, a peptide with a high tendency to aggregate. In silico simulations demonstrate that lactose and 2-hydroxypropyl-beta-cyclodextrin (2-HP beta CD) influence glucagon aggregation differently: lactose stabilizes glucagon by increasing the alpha-helical content, while 2-HP beta CD disrupts protein-protein interactions. According to the simulations, 2-HP beta CD is particularly effective at preserving the monomeric form of glucagon. Experimental validation with microfluidic modulation spectroscopy (MMS) confirms these findings, showing that glucagon in the presence of 2-HP beta CD remains structurally stable, supporting the antiaggregation effect of this excipient. This research provides essential insights into glucagon aggregation obtained through a new powerful tool for monitoring the critical properties of peptide aggregation, suggesting new strategies for addressing this challenge in therapeutic peptide development.
File in questo prodotto:
File Dimensione Formato  
a-2024_MP_21_3815-3823.pdf

non disponibili

Descrizione: a-2024_MP_21_3815-3823
Tipologia: 2a Post-print versione editoriale / Version of Record
Licenza: Non Pubblico - Accesso privato/ristretto
Dimensione 2.93 MB
Formato Adobe PDF
2.93 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
a-2024_MP_21_3815-3823_(authors-version).pdf

embargo fino al 25/07/2025

Descrizione: a-2024_MP_21_3815-3823_(authors-version)
Tipologia: 2. Post-print / Author's Accepted Manuscript
Licenza: PUBBLICO - Tutti i diritti riservati
Dimensione 999.74 kB
Formato Adobe PDF
999.74 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11583/2992046